TriSalus 8-K Signals Active Communications Under Securities Rules

Ticker: TLSIW · Form: 8-K · Filed: Jan 5, 2024 · CIK: 1826667

Trisalus Life Sciences, Inc. 8-K Filing Summary
FieldDetail
CompanyTrisalus Life Sciences, Inc. (TLSIW)
Form Type8-K
Filed DateJan 5, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001, $11.50
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: corporate-action, regulatory-filing, investor-relations

TL;DR

**TriSalus filed an 8-K signaling active investor communications, likely ahead of a major corporate event.**

AI Summary

TriSalus Life Sciences, Inc. filed an 8-K on January 5, 2024, indicating it is satisfying filing obligations related to written communications under Rule 425 of the Securities Act and soliciting material under Rule 14a-12 of the Exchange Act. This suggests the company is actively engaged in communications that could be related to a significant corporate event, such as a merger, acquisition, or a major financing round. For investors, this matters because these types of communications often precede or accompany material changes that can impact the stock's valuation and future prospects.

Why It Matters

This filing indicates TriSalus is making specific communications to investors, which often precedes or accompanies significant corporate actions that could impact the stock price.

Risk Assessment

Risk Level: medium — The filing itself is administrative, but the underlying events it points to (potential M&A, financing) carry inherent market and execution risks.

Analyst Insight

Investors should monitor TriSalus Life Sciences, Inc. for subsequent filings or press releases that elaborate on the nature of the communications indicated by this 8-K, as they could signal upcoming material corporate events.

Key Players & Entities

  • TriSalus Life Sciences, Inc. (company) — the registrant filing the 8-K
  • January 5, 2024 (date) — date of earliest event reported and filing date
  • Rule 425 (person) — a rule under the Securities Act (17 CFR 230.425)
  • Rule 14a-12 (person) — a rule under the Exchange Act (17 CFR 240.14a-12)

Forward-Looking Statements

  • TriSalus Life Sciences, Inc. will announce a significant corporate event, such as a merger, acquisition, or major financing round, within the next 3-6 months. (TriSalus Life Sciences, Inc.) — medium confidence, target: 2024-07-05

FAQ

What is the primary purpose of TriSalus Life Sciences, Inc.'s 8-K filing on January 5, 2024?

The primary purpose of TriSalus Life Sciences, Inc.'s 8-K filing on January 5, 2024, is to indicate that the filing simultaneously satisfies obligations under Rule 425 of the Securities Act and Rule 14a-12 of the Exchange Act, related to written communications and soliciting material, respectively.

What specific SEC rules are referenced in this 8-K filing?

This 8-K filing specifically references Rule 425 under the Securities Act (17 CFR 230.425) and Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

What is the registrant's telephone number as listed in the filing?

The registrant's telephone number, including area code, is listed as (888) 321-5212.

Where is TriSalus Life Sciences, Inc.'s principal executive office located?

TriSalus Life Sciences, Inc.'s principal executive office is located at 6272 W. 91st Ave., Westminster, Colorado 80031.

What was the former name of TriSalus Life Sciences, Inc. and when did the name change occur?

The former name of TriSalus Life Sciences, Inc. was MedTech Acquisition Corp, and the date of the name change was September 30, 2020 (20200930).

Filing Stats: 604 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-01-05 16:28:31

Key Financial Figures

  • $0.0001 — ge on which registered Common Stock, $0.0001 par value per share TLSI Nasdaq Glo
  • $11.50 — of Common Stock at an exercise price of $11.50 per share TLSIW Nasdaq Global Marke

Filing Documents

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. TriSalus Life Sciences, Inc. (the "Company") may use a slide presentation, in whole or in part, from time to time in presentation to investors, analysts and others that includes preliminary sales information for the year ended December 31, 2023, as well as a business and product update. A copy of the slide presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. A copy of the slide presentation is also available on the Company's website at https://trisaluslifesci.com/. The information in this Item 2.02, including Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to liabilities under that section, and shall not be deemed to be incorporated by reference into the filings of the registrant under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings. This Current Report on 8-K will not be deemed an admission as to the materiality of any information contained in this Item 2.02, including Exhibit 99.1.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Investor Presentation, dated January 2024. 104 Cover page Interactive data file (embedded within the inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 5, 2024 TRISALUS LIFE SCIENCES, INC. By: /s/ Sean Murphy Sean Murphy Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.